A Phase I, Multicentre, Open-label, Self-control Study to Evaluate the Pharmacokinetics of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection in Adolescent and Adult Patients With Hemophilia A
Phase of Trial: Phase I
Latest Information Update: 17 Mar 2019
Price : $35 *
At a glance
- Drugs FRSW 107 (Primary) ; Octocog alfa (Primary)
- Indications Haemophilia A
- Focus Pharmacokinetics
- Sponsors Kaifeng Pharmaceutical
- 03 Mar 2019 Planned End Date changed from 31 May 2019 to 31 Oct 2019.
- 03 Mar 2019 Planned primary completion date changed from 31 Mar 2019 to 31 Oct 2019.
- 27 Nov 2018 New trial record